Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

181 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
De Laurentiis M, Borstnar S, Campone M, Warner E, Bofill JS, Jacot W, Dent S, Martin M, Ring A, Cottu P, Lu J, Ciruelos E, Azim HA, Chatterjee S, Zhou K, Wu J, Menon-Singh L, Zamagni C. De Laurentiis M, et al. Among authors: azim ha. Breast Cancer Res Treat. 2021 Oct;189(3):689-699. doi: 10.1007/s10549-021-06334-0. Epub 2021 Aug 19. Breast Cancer Res Treat. 2021. PMID: 34414532 Free PMC article. Clinical Trial.
Trastuzumab versus lapatinib: the cardiac side of the story.
Azim H, Azim HA Jr, Escudier B. Azim H, et al. Among authors: azim ha jr. Cancer Treat Rev. 2009 Nov;35(7):633-8. doi: 10.1016/j.ctrv.2009.06.007. Epub 2009 Jul 28. Cancer Treat Rev. 2009. PMID: 19640652 Review.
A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer.
Mubarak N, Gaafar R, Shehata S, Hashem T, Abigeres D, Azim HA, El-Husseiny G, Al-Husaini H, Liu Z. Mubarak N, et al. Among authors: azim ha. BMC Cancer. 2012 Sep 24;12:423. doi: 10.1186/1471-2407-12-423. BMC Cancer. 2012. PMID: 23006447 Free PMC article. Clinical Trial.
Adjuvant Subcutaneous Trastuzumab for HER2-Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study.
Jung KH, Ataseven B, Verrill M, Pivot X, De Laurentiis M, Al-Sakaff N, Lauer S, Shing M, Gligorov J, Azim HA. Jung KH, et al. Among authors: azim ha. Oncologist. 2018 Oct;23(10):1137-1143. doi: 10.1634/theoncologist.2018-0065. Epub 2018 Jul 17. Oncologist. 2018. PMID: 30018134 Free PMC article. Clinical Trial.
Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
De Laurentiis M, Borstnar S, Campone M, Warner E, Bofill JS, Jacot W, Dent S, Martin M, Ring A, Cottu P, Lu J, Ciruelos E, Azim HA, Chatterjee S, Zhou K, Wu J, Menon-Singh L, Zamagni C. De Laurentiis M, et al. Among authors: azim ha. Breast Cancer Res Treat. 2022 Jan;191(1):223-224. doi: 10.1007/s10549-021-06374-6. Breast Cancer Res Treat. 2022. PMID: 34625861 Free PMC article. No abstract available.
181 results